Clinical trials: Stage IIIB NSCLC
Non Small Cell Lung Carcinoma
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
The main purpose of this research study is to see if adding fulvestrant (Faslodex) to erlotinib (Tarceva) is effective in patients with stage IIIb/IV Non-Small Cell Lung Cancer.
- Trial name
- NCT00592007
- Testing
- Fulvestrant and Erlotinib
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Lyudmila Bazhenova, M.D.
Non-Small Cell Lung Cancer
Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer
This is a Phase II, open-label trial of Taxotere® + ZD1839 in elderly patients with Stage III-b or IV NSCLC who have received no prior chemotherapy for metastatic disease.
- Trial name
- NCT00231465
- Testing
- docetaxel (Taxotere®), ZD1839
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer (NSCLC)
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
This study will evaluate the surgical safety and feasibility of atezolizumab plus tiragolumab alone or in combination with platinum-based chemotherapy as neoadjuvant treatment for participants with previously untreated locally…
- Trial name
- NCT04832854
- Testing
- Atezolizumab, Tiragolumab, Carboplatin
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
This study looked at how effective the study drug (tepotinib) was at stopping the growth and spread of lung cancer. This study also measures a number of other things including safety of the study drug and the side effects, how…
- Trial name
- NCT02864992
- Testing
- Tepotinib
- Where
- 176 sites in United States, Austria and 13 more
- Volunteers
- 337 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Lung Cancer, Metastatic Cancer
Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura
RATIONALE: Photodynamic therapy uses a drug, such as porfimer sodium, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00601848
- Testing
- chemotherapy, porfimer sodium, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Lung Cancer
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00438204
- Testing
- bevacizumab, gemcitabine hydrochloride, pemetrexed disodium
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer
FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or IV non-small cell lung cancer (NSCLC).
- Conditions
- Malignant Pleural Effusion, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00564733
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Washington
Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
This phase II trial studies how well giving a hypofractionated boost to the primary tumor before standard chemotherapy and radiation therapy works in treating patients with stage II or III non-small cell lung cancer that cannot…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
- Trial name
- NCT02262325
- Testing
- hypofractionated radiation therapy, cisplatin, etoposide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal…
- Trial name
- NCT00547105
- Testing
- Erlotinib, SBRT
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer
S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00288054
- Testing
- cetuximab, docetaxel, radiation therapy
- Where
- 77 sites in United States
- Volunteers
- 24 people
- Sponsor
- SWOG Cancer Research Network
Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
This phase II trial studies the effect of bintrafusp alfa with pemetrexed and platinum-based chemotherapy (carboplatin or cisplatin) in treating patients with EGFR mutant non-small cell lung cancer that have spread to nearby…
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
- Trial name
- NCT04971187
- Testing
- Bintrafusp Alfa, Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer
Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer
This phase I/II trial (phase I closed to accrual as of 09/29/2009) is studying the side effects and best dose of bortezomib, paclitaxel, and carboplatin when given with radiation therapy and to see how well they work in treating…
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- NCT00093756
- Testing
- 3-dimensional conformal radiation therapy, bortezomib, paclitaxel
- Where
- 143 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00445848
- Testing
- bevacizumab, erlotinib hydrochloride
- Where
- 153 sites in United States
- Volunteers
- 89 people
- Sponsor
- SWOG Cancer Research Network
Lung Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00528775
- Testing
- HPPH, endoscopic procedure
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT00729612
- Testing
- carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, protein expression analysis
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Greg Otterson
Neoplasms
Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.
- Trial name
- NCT02588612
- Testing
- letetresgene autoleucel (GSK3377794), Cyclophosphamide, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer
Imatinib Mesylate and Paclitaxel in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well giving imatinib mesylate together with paclitaxel works in treating older patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00408460
- Testing
- imatinib mesylate, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab…
- Trial name
- NCT00343291
- Testing
- Cetuximab, Bevacizumab, Paclitaxel
- Where
- 43 sites in United States
- Volunteers
- 121 people
- Sponsor
- Eli Lilly and Company
Non-Small-Cell Lung Carcinoma
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred…
- Trial name
- NCT00404924
- Testing
- ZD6474 (vandetanib), Best Supportive Care
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 1,140 people
- Sponsor
- Genzyme, a Sanofi Company